For the ABU Qualifying (Part 1) Examination, residents need to possess basic urologic knowledge and an understanding of current American Urological Association practice guidelines. To fulfill this need, the AUA developed this course to disseminate current urologic knowledge and successfully prepare residents for the ABU examination. This course is also of interest to practicing urologists as well as others, including allied health professionals, looking for a thorough review of basic urologic topics.

Get the most out of your study time and preparation by marking off your calendar and registering for the Live Course!

The 2026 Live Program Includes:

• New Location--St. Louis, MO
• Live Presentations
• Audience Interaction
• Lunch with the Experts
• Q&A
• Polling/ Practice Questions

Live Course Only registrants may also choose to purchase our most popular package by adding on the Annual Review Course Syllabus and/ or the Annual Review Couse Webcast Upgrade for the most comprehensive learning experience!

Syllabus: This 3-volume book set includes the black and white pdfs of all of the course content. Printed at two slides per page, this is a great additional option for those who prefer to take handwritten notes during the lecutres.

Webcast Upgrade: Extend your learning with the webcast upgrade which gives you access to all of thecourse webcasts. Conveniently watch or listen to content anytime, anywhere. Webcasts will be available to ivew on Wednesday, June 11, 2026.

AUA Guarantee: This course is backed by the AUA Guarantee: If you fail the boards, then we will pay for you to retake our in person course as space permits or until capacity is reached. (Applicable 2025 registrants please call 1-800-908-9414)

---

Registration Fees:

Early Bird Registration - On or before April 24, 2026 to save 25%

Membership Category	Early Bird Registration On or Before April 24, 2026	Standard Registration On or After April 25, 2026	Webcast* Upgrade	Syllabus*
Member	$1035	$1295	$315	$226
Non-Member	$1295	$1615	$315
Member Resident/Allied	$570	$712	$157
Non-Member Resident/Allied	$712	$890	$157

*The Annual Review Course Webcast and Syllabus are NOT included in the purchase of the Live Course Only but are two separate add-on options for additional fees. All syllabi will be picked up onsite during registration. The syllabus is not available for purchase for Webcast Only registrants.

• Residents
• Urologists

After participation in this CME activity, participants will be able to:

1. Demonstrate core knowledge of urology necessary for American Board of Urology (ABU) Qualifying (Part 1).
2. Employ basic, generally accepted urological practices for effective, high-quality patient care.
3. Utilize AUA Guidelines for appropriate patient evaluation and management.

Education Council Disclosures:
Education Council Disclosures_2025

COI Review Work Group Disclsoures: 
COI Review Work Group Disclosures_2025

Faculty Disclosures:
Faculty disclosures will be posted here prior to the course. 

AUA Office of Education Staff has nothing to disclose. 
All relevant financial relationships have been mitigated.

Annual Review Course

June 6 - 8, 2026
St. Louis, MO

Scientific Program

Saturday, June 6, 2026
6:30 – 7:15 a.m.	Regristration/Breakfast
7:15 – 7:20 a.m.	Welcome Message Michael Coburn, MD, FACS Chair of Urology, Baylor
7:20 – 7:30 a.m.	Introduction Kevin Koo, MD, MPH, MPhil and Kristen R. Scarpato, MD, MPH
BLADDER CANCER
7:30 – 8:15 a.m.	Epidemiology and Anatomy Staging and Risk Stratification of Non-Muscle Invasive Bladder Cancer (NMIBC) Treatment and Surveillance of NMIBC Kristen R. Scarpato, MD, MPH
8:15 – 9:15 a.m.	Staging and Risk Stratification of Muscle Invasive Bladder Cancer Multidisciplinary Treatment including Radical Cystectomy, Lymphadenectomy, Peri-Operative Chemotherapy and Chemoradiation Therapy Metabolic Derangements that Occur with Diversions Other Bladder Sparing Treatments Treatment of Metastatic Disease Jennifer M. Taylor, MD, MPH
9:15 – 9:35 a.m.	Break
9:35 – 9:55 a.m.	Bladder Cancer Review Questions Kristen R. Scarpato, MD, MPH & Jennifer M. Taylor, MD, MPH
RENAL AND URETERAL TUMORS
9:55 – 11:20 a.m.	Epidemiology, Anatomy, Diagnosis and Imaging (Including Evaluation of Renal Masses) Treatment of Localized Disease (Including Role of Partial Nephrectomy) Treatment of Metastatic Disease Transitional Cell Carcinoma Phillip M. Pierorazio, MD
PENILE AND URETHRAL CANCER
11:20 – 12:05 p.m.	Epidemiology Diagnosis and Staging Imaging and Treatment Phillip M. Pierorazio, MD
12:40 – 1:45 p.m.	Lunch*
TESTICULAR TUMORS
1:05 – 2:05 p.m.	Epidemiology, Diagnosis, Staging and Imaging (including the Role of Markers and CIS) Treatment of Seminoma Treatment of Non-Seminomatous Germ Cell Tumors Harras Zaid, MD
PROSTATE CANCER
2:05 – 3:20 p.m.	Epidemiology, Screening and Diagnosis, Staging Treatment of Localized Cancer: Watchful Waiting, Active Surveillance, Surgery Radiation, and Hormonal Therapy Treatment of Advanced Cancer: Biochemical Recurrence, Metastatic Hormone Sensitive Prostate Cancer, Non-Metastatic and Metastatic Castration Resistant Prostate Cancer Genetic Testing Kristen R. Scarpato, MD, MPH
3:20 – 3:35 p.m.	Break
TRAUMA AND RECONSTRUCTION
3:35 – 4:50 p.m.	Renal and Ureteral Trauma and Reconstruction Bladder and Urethral Trauma and Reconstruction Genital Trauma: Evaluation and Management Surgical Management of Male Incontinence Jay Simhan, MD, FACS
4:50 p.m.	Meeting Adjourns
Sunday, June 7, 2026
6:30 – 7:15 a.m.	Breakfast
ANATOMY AND EMBRYOLOGY
7:15 – 9:00 a.m.	Applied Anatomy Embryology Howard B. Goldman, MD, FACS
ERECTILE DYSFUNCTION
9:00 – 10:00 a.m.	Physiology of Erection, Pathophysiology of Erectile Dysfunction Evaluation and Management of Erectile Dysfunction Pathophysiology, Evaluation and Management of Priapism Pathophysiology, Evaluation and Management of Peyronie’s Disease Ryan P. Terlecki MD, FACS
10:00 – 10:20 a.m.	Break
RENAL AND URETHRAL TUMORS
10:00 – 11:25 a.m.	Epidemiology, Anatomy, Diagnosis and Imaging (Including Evaluation of Renal Masses) Treatment of Localized Disease (including Role of Partial Nephrectomy) Treatment of Metastatic Disease Transitional Cell Carcinoma Robert G. Uzzo, MD, MBA, FACS
11:25 – 11:35 a.m.	Break
INFERTILITY
10:20 – 11:50 a.m.	Physiology and Pathophysiology of Male Reproduction  Evaluation of the Infertile Male Treatment of the Infertile Male (Surgical and Non-surgical) Hypogonadism Testosterone Replacement Matt Coward, MD
URINARY TRACT INFECTION
11:50 a.m. – 12:20 p.m.	Urinary Tract Infections Una Lee, MD
12:20 – 1:20 p.m.	Lunch
INTERSTITIAL CYSTITIS AND SEXUALLY TRANSMITTED DISEASES
1:20 – 1:50 p.m.	Interstitial Cystitis Sexually Transmitted Diseases (Gonorrhea, Chlamydia, AIDS and others) Anne P. Cameron, MD, FRCSC, FPMRS
FEMALE PELVIC MEDICINE, FEMALE SEXUAL DYSFUNCTION, URODYNAMICS AND NEUROUROLOGY
1:50 – 3:05 p.m.	Overactive Bladder/Urgency Incontinence Stress Urinary Incontinence Pelvic Organ Prolapse Urethral Diverticulum Urinary Fistula Howard B. Goldman, MD, FACS
3:05 – 3:25 p.m.	Break
3:25 – 4:25 p.m.	Female Sexual Dysfunction Neurourology Anne P. Cameron, MD, FRCSC, FPMRS
4:25 – 5:05 p.m.	Urodynamics Basics Tracing Review Anne P. Cameron, MD, FRCSC, FPMRS
5:05 p.m.	Meeting Adjourns
Monday, June 8, 2026
PEDIATRIC UROLOGY
7:15 — 8:00 a.m.	Congenital Urinary Tract Abnormalities UPJ Obstruction, UVJ Obstruction (Megaureter) Ureteroceles Cystic Kidney Disease Posterior Urethral Valves Prune Belly Syndrome Vesicoureteral Reflux Bruce J. Schlomer, MD
8:00 – 8:45 a.m.	Pediatric Urinary Incontinence and Bladder Disorders Voiding Dysfunction and Neurogenic Bladder Developmental Anomalies of the Bladder Urinary Tract Infection and Secondary Reflux Management of Neurogenic and Non-Neurogenic Bladder Pediatric Metabolic Stones Diana K. Bowen, MD
9:15 – 9:45 a.m.	Pediatric Urological Oncology Wilms’ Tumor and Other Renal Tumors Rhabdomyosarcoma Neuroblastoma Testis Tumors Diana K. Bowen, MD
9:45 – 10:05 a.m.	Break
10:05– 10:35 a.m.	Pediatric Review Questions Diana K. Bowen, MD & Bruce J. Schlomer, MD
RENAL MEDICINE
10:35 – 11:20 a.m.	Renal Physiology (including Fluid and Electrolytes) Renal Transplantation Renal Vascular Disease Nicholas G. Cowan, MD
ADRENAL
11:20 a.m. – 12:05 p.m.	Epidemiology, Diagnosis and Imaging (including Cushings, Hyperaldosteronism, Pheochromocytoma, Cancer and the Incidentally Found Adrenal Mass) Management (including Pheochromocytoma, Cancer, Hyperaldosteronism, Incidentaloma and Metastatic Disease) Wesley A. Mayer, MD
12:05 – 1:00 p.m.	Lunch
BPH
1:00 – 1:45 p.m.	Evaluation Medical Management Surgical Management Ramy Goueli, MD
GU RADIOLOGY
1:45 – 2:45 p.m.	Basics of MR, CT, US, VCUG Solid and Cystic Renal Masses (CT and MR) Transitional Cell Carcinoma Prostate MRI Adrenal Imaging Scrotal Imaging Retroperitoneal Tumors Radiation Basic Principles Vinay Prabhu, MD, MS
2:24- 3:00 p.m.	Break
LAPAROSCOPY
3:00– 3:30 p.m.	Physiology and Complications Wesley A. Mayer, MD
UROLITHIASIS
3:30 – 5:00 p.m.	Epidemiology, Pathophysiology Evaluation and Medical Management Surgical Management of Stone Disease Kevin Koo, MD, MPH, MPhil
5:00 p.m.	Meeting Adjourns

ACCREDITATION: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: The American Urological Association designates this live activity for a maximum of 24.00 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit^TM.

EVIDENCE BASED CONTENT: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of relevant financial relationships that result in conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.